Jorge Cortes, MD
Jorge Cortes serves as the director for the Georgia Cancer Center and Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer after spending 27 years at MD Anderson Cancer Center as Deputy Chair Department of Leukemia, Chair of AML and CML Sections, and Leukemia Fellowship Program Director. He was also the Deputy Division Head for the Cancer Network. He was chair of the executive IRB at MD Anderson from 2012 to 2019, and Chair of the Executive Committee of the Medical Staff from 2012 to 2015. He has over 230 grants and research contracts where he was principal investigator and led the approval of 4 leukemia drugs. He has published more than 1300 manuscripts and has received multiple awards including the John Kenny Award from The Leukemia & Lymphoma Society 2006, The Otis W. & Pearl L. Walters Faculty Achievement Award in Clinical Research, MDACC, in 2007, the William Randolph Hearst Foundations Faculty Achievement Award in Education, MDACC, in 2013, and the John Goldman Prize from the International CML Foundation in 2018. He was included in the Best Scientist (all fields) in the World Ranking at 196 in United States and 291 in the world for 2022 by Research.com. Dr. Cortes is a member of the National Academy of Medicine in Mexico and has served as Associate Editor for Blood and as member of the National Board of Directors of the Leukemia & Lymphoma Society. He is Co-Founder and Co-Director of the International CML Foundation and Vice Chair of the Publications Committee for the American Society of Hematology. He is a member of the European LeukemiaNet panel for CML recommendations since 2006 and he is listed in Georgia 500 Top Individuals in their fields by Georgia Trend Magazine, 2022.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:NovartisTopic:CML, AMLDate added:03/14/2023Date updated:04/08/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:PfizerTopic:CML, AML, ALLDate added:03/14/2023Date updated:04/08/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:TakedaTopic:CMLDate added:03/14/2023Date updated:04/08/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:AbbvieTopic:AML, MPNDate added:03/14/2023Date updated:04/08/2024
-
Attribution:OtherType of financial relationship:OtherIneligible company:Sun PharmaTopic:CMLDate added:03/14/2023Date updated:04/08/2024